PE33396A1 - COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS - Google Patents
COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMSInfo
- Publication number
- PE33396A1 PE33396A1 PE1995272088A PE27208895A PE33396A1 PE 33396 A1 PE33396 A1 PE 33396A1 PE 1995272088 A PE1995272088 A PE 1995272088A PE 27208895 A PE27208895 A PE 27208895A PE 33396 A1 PE33396 A1 PE 33396A1
- Authority
- PE
- Peru
- Prior art keywords
- nicotine
- composition
- ansia
- smoking
- symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
CARACTERIZADA POR SER LIQUIDA QUE COMPRENDE NICOTINA Y CAFEINA, EN DONDE LA COMPOSICION SUMINISTRA: A) DESDE 0,01 mg A 2 mg DE NICOTINA; B) DESDE 3 mg A 20 mg DE CAFEINA; C) UNO O MAS VEHICULOS FARMACEUTICOS ACEPTABLES; D) DESDE 0,5% A 10% DE UN AGENTE TENSIOACTIVO FARMACEUTICAMENTE ACEPTABLE; E) DESDE 0,001% A 2% DE UN AGENTE DE CONSERVACION FARMACEUTICAMENTE ACEPTABLE; F) DESDE 0,01% A 5% DE UN HUMECTANTE ACEPTABLE. LA SOLUCION SE ENCUENTRA EN FORMA DE UNA SOLUCION SALINA ACUOSA QUE COMPRENDE DESDE 0,5% A 1% DE CLORURO DE SODIO Y DESDE 95% A 99,5% DE AGUA PURIFICADACHARACTERIZED AS A LIQUID THAT INCLUDES NICOTINE AND CAFFEINE, WHERE THE COMPOSITION PROVIDES: A) FROM 0.01 mg TO 2 mg OF NICOTINE; B) FROM 3 mg TO 20 mg OF CAFFEINE; C) ONE OR MORE ACCEPTABLE PHARMACEUTICAL VEHICLES; D) FROM 0.5% TO 10% OF A PHARMACEUTICALLY ACCEPTABLE SURFACE AGENT; E) FROM 0.001% TO 2% OF A PHARMACEUTICALLY ACCEPTABLE CONSERVATION AGENT; F) FROM 0.01% TO 5% OF AN ACCEPTABLE MOISTURIZER. THE SOLUTION IS IN THE FORM OF AN AQUEOUS SALT SOLUTION, INCLUDING FROM 0.5% TO 1% SODIUM CHLORIDE AND FROM 95% TO 99.5% PURIFIED WATER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26426294A | 1994-06-23 | 1994-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE33396A1 true PE33396A1 (en) | 1996-08-19 |
Family
ID=23005260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1995272088A PE33396A1 (en) | 1994-06-23 | 1995-06-22 | COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS |
Country Status (6)
Country | Link |
---|---|
AU (1) | AU2703695A (en) |
IL (1) | IL114129A0 (en) |
MA (1) | MA23588A1 (en) |
PE (1) | PE33396A1 (en) |
WO (1) | WO1996000071A1 (en) |
ZA (1) | ZA955032B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO108596A0 (en) * | 1996-07-18 | 1996-08-08 | Collier, Gregory | Treatment of obesity |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
WO2003057188A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
EP1625333A1 (en) | 2003-05-21 | 2006-02-15 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
ES2594867T3 (en) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US20110053988A1 (en) * | 2009-08-29 | 2011-03-03 | Jorge Alberto Cassara | Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke |
DE102011114094A1 (en) * | 2011-09-21 | 2013-03-21 | F. Holzer Gmbh | Stimulating and invigorating nasal spray and nose drops |
EP3442583B1 (en) * | 2016-04-12 | 2024-04-10 | Arturo Solis Herrera | Composition comprising nicotine for treating bleeding of the nasal or paranasal mucosa |
WO2019200427A1 (en) * | 2018-04-16 | 2019-10-24 | Barista Mist Pty Ltd | Caffeine compositions and methods of use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778677A (en) * | 1981-07-09 | 1988-10-18 | Ebbesen Gerald K | Method for treatment of nicotine craving |
US4568676A (en) * | 1983-11-25 | 1986-02-04 | Thomas Jefferson University | Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor |
DE3506406A1 (en) * | 1985-02-23 | 1986-08-28 | Hans-Josef 5600 Wuppertal Stromberg | DEVICE FOR THE DEWNING OF EATING, DRINKING, SMOKING AND / OR ADDICTIVE Habits |
US5051426A (en) * | 1990-03-27 | 1991-09-24 | Parnell Pharmaceuticals, Inc. | Method for effecting withdrawal from drug dependency |
-
1995
- 1995-05-16 MA MA23931A patent/MA23588A1/en unknown
- 1995-06-09 AU AU27036/95A patent/AU2703695A/en not_active Abandoned
- 1995-06-09 WO PCT/US1995/007425 patent/WO1996000071A1/en active Application Filing
- 1995-06-13 IL IL11412995A patent/IL114129A0/en unknown
- 1995-06-19 ZA ZA955032A patent/ZA955032B/en unknown
- 1995-06-22 PE PE1995272088A patent/PE33396A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA955032B (en) | 1996-03-11 |
IL114129A0 (en) | 1995-10-31 |
WO1996000071A1 (en) | 1996-01-04 |
MA23588A1 (en) | 1995-12-31 |
AU2703695A (en) | 1996-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25374A1 (en) | APOMORPHINE COMPOSITIONS USEFUL IN THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | |
HK1003978A1 (en) | Composition for the treatment of schizophrenia | |
CO5271759A1 (en) | FORMULATION IN SOLUTION CONTAINING A MIXTURE OF SOLVENTS | |
RU94041223A (en) | Agent for motoneuron disease treatment | |
SE8903914D0 (en) | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | |
ES2167453T3 (en) | MEDICINAL SUPPLY COMPOSITION CONTAINING CHITOSANE OR DERIVATIVE OF THE SAME WITH A POTENTIAL Z. DEFINED. | |
KR970704429A (en) | USE OF DROLOXIFENE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
DE3851152D1 (en) | CYCLOSPORINE EYE PRODUCTS. | |
PE33396A1 (en) | COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS | |
PE68899A1 (en) | COMPOSITION CONTAINING PARACETAMOL | |
ES8305363A1 (en) | Topical formulations of 9-(2-hydroxyethoxymethyl) guanine. | |
AR015744A1 (en) | USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY | |
MX9205568A (en) | PHARMACEUTICAL COMPOSITION CONTAINING AMOUNTS OF 5-AMINO-1BETA-D-RIBOFURANOSIL-IMIDAZOLE-4-CARBOXAMIDE. | |
ES2142430T3 (en) | PHARMACEUTICAL COMPOUNDS IN THE FORM OF GEL CONTAINING SALTS OF CHONDROITIN SULPHATE SUITABLE FOR ORAL ADMINISTRATION. | |
CO4960654A1 (en) | METHOD FOR THE TREATMENT OF PHYSIOLOGICAL DISEASES RELATED TO THE USE OR SEQUELS CAUSED BY THE USE OF COCAINE OR OTHER PSYCHOMOTOR STIMULANTS | |
BR0111325A (en) | process of controlling snoring in a person, and product adapted for use in treating snoring | |
ES2039433T3 (en) | A PHARMACEUTICAL FORMULATION. | |
ATE81462T1 (en) | GLYCOSAMINOGLYCAN FOR THE TREATMENT OF DIABETIC MICROANGIOPATHIA. | |
KR920702225A (en) | Pharmaceutical composition | |
KR920014474A (en) | Preparations for Gallstone Collapse | |
ES2092559T3 (en) | PHARMACEUTICAL FORMULATION CONTAINING PENCICLOVIR. | |
KR880009656A (en) | Treatment or prophylaxis of local periodontal disease | |
ES2128353T3 (en) | TOPIC COMPOSITION CONTAINING PENCICLOVIR. | |
AR044697A1 (en) | PHARMACEUTICAL FORMULATIONS THAT INCLUDE AMOXYCLINE AND CLAVULANATE | |
KR880010762A (en) | Composition and Method for Treatment of peptic Ulcers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |